Press Release Archives - MOMA Therapeutics

MOMA Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., November 6, 2024 — MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that company management will participate in…

Bayer and MOMA Therapeutics enter collaboration and license agreement in Oncology

Berlin, Germany and Cambridge, Mass., USA, October 8, 2024 – Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced…

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor

– First patient dosed in a first-in-human study to assess safety and tolerability of MOMA-313 in patients with cancers carrying mutations in DNA repair genes – – MOMA-313 is a…

MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer

CAMBRIDGE, Mass., June 25, 2024— MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the…

Archive for Press Release

MOMA Therapeutics to Participate in Upcoming Investor Conferences

Bayer and MOMA Therapeutics enter collaboration and license agreement in Oncology

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor

MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies

MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors

MOMA Therapeutics Announces $150 Million Series B Financing

MOMA Therapeutics Appoints Hans Bitter, Ph.D., as Senior Vice President and Head, Data Science

Fierce Biotech names MOMA Therapeutics as one of its “Fierce 15” Biotech Companies of 2021